145040-37-5 | Candesartan cilexetil

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$15.00	$10.00
10mg	98%	in stock	$18.00	$12.00
50mg	98%	in stock	$22.00	$15.00
1g	98%	in stock	$25.00	$18.00
5g	98%	in stock	$53.00	$37.00
10g	98%	in stock	$96.00	$67.00
25g	98%	in stock	$219.00	$153.00

Description

• Catalog Number: AI36175
• Chemical Name: Candesartan cilexetil
• CAS Number: 145040-37-5
• Molecular Formula: C33H34N6O6
• Molecular Weight: 610.6597
• MDL Number: MFCD00871371
• SMILES: CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)c(ccc2)C(=O)OC(OC(=O)OC1CCCCC1)C
• NSC Number: 758697

Computed Properties

• Complexity: 962
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 45
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 13
• Undefined Atom Stereocenter Count: 1
• XLogP3: 7

Literature

• Candesartan ameliorates arsenic-induced hypertensive vascular remodeling by regularizing angiotensin II and TGF-beta signaling in rats.

  Toxicology 20161230

• Candesartan cilexetil attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR.

  International journal of cardiology 20160701

• Mitofusin 2 ameliorates aortic remodeling by suppressing ras/raf/ERK pathway and regulating mitochondrial function in vascular smooth muscle cells.

  International journal of cardiology 20150115

• Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.

  Hypertension research : official journal of the Japanese Society of Hypertension 20140901

• Comparative study of the AT₁ receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers.

  Biochimica et biophysica acta 20121201

• Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats.

  Nanomedicine : nanotechnology, biology, and medicine 20120701

• LC-MS/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics.

  Bioanalysis 20120601

• Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120501

• Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120501

• Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan.

  Expert review of cardiovascular therapy 20120501

• Assessment of enzymatic prodrug stability in human, dog and simulated intestinal fluids.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120401

• Acute treatment with candesartan cilexetil, an angiotensin II type 1 receptor blocker, improves insulin sensitivity in high-fructose-diet-fed rats.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20120401

• Candesartan cilexetil improves angiotensin II type 2 receptor-mediated neurite outgrowth via the PI3K-Akt pathway in fructose-induced insulin-resistant rats.

  Diabetes 20120401

• Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.

  Clinical therapeutics 20120401

• Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer.

  The American journal of pathology 20120301

• Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin action in rats on high-fat diet.

  Life sciences 20120227

• Candesartan cilexetil in children and adolescents aged 1 to <17 years with hypertension: profile report.

  Paediatric drugs 20120201

• Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: involvement of ACE2-Ang (1-7)-mas axis.

  Toxicology 20120127

• A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.

  Experimental animals 20120101

• Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats.

  Circulation journal : official journal of the Japanese Circulation Society 20120101

• Candesartan cilexetil.

  Profiles of drug substances, excipients, and related methodology 20120101

• A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.

  PloS one 20120101

• Pharmacokinetic interaction study with fixed high dose combinations of candesartan cilexetil and hydrochlorothiazide.

  International journal of clinical pharmacology and therapeutics 20111201

• Candesartan in the treatment of hypertension: what have we learnt in the last decade?

  Expert opinion on drug safety 20111101

• Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.

  Journal of hypertension 20111101

• Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus.

  Current medical research and opinion 20111101

• Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR.

  Journal of pharmaceutical and biomedical analysis 20110910

• Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study.

  Expert review of cardiovascular therapy 20110901

• Candesartan cilexetil: an update.

  Expert opinion on pharmacotherapy 20110801

• Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.

  Clinical therapeutics 20110801

• Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions.

  Current drug delivery 20110701

• Reflex systemic sympatho-neural response to brachial adenosine infusion in treated heart failure.

  European journal of heart failure 20110501

• Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state.

  Journal of pharmaceutical and biomedical analysis 20110220

• [EFFECTIVE data. New effectiveness dimensions in antihypertensive combination therapy].

  MMW Fortschritte der Medizin 20110127

• [Focus on compliance. Rapid goal attainment in hypertension].

  MMW Fortschritte der Medizin 20110127

• Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism.

  Journal of controlled release : official journal of the Controlled Release Society 20110120

• Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).

  Vascular health and risk management 20110101

• Identification and determination of selected angiotensin II receptor antagonist group drugs by HPLC method.

  Acta poloniae pharmaceutica 20110101

• Differential clinical profile of candesartan compared to other angiotensin receptor blockers.

  Vascular health and risk management 20110101

• Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.

  Bioorganic & medicinal chemistry 20101215

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Positive influence of AT(1) receptor antagonism upon the impaired celiprolol-induced vasodilatation in aorta from spontaneously hypertensive rats.

  European journal of pharmacology 20101010

• LC and LC-MS/TOF studies on stress degradation behaviour of candesartan cilexetil.

  Journal of pharmaceutical and biomedical analysis 20100708

• Colloid formation by drugs in simulated intestinal fluid.

  Journal of medicinal chemistry 20100527

• Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.

  Journal of hypertension 20100501

• Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100301

• Solid self-microemulsifying formulation for candesartan cilexetil.

  AAPS PharmSciTech 20100301

• Hypertension after kidney transplantation: still a SECRET?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100301

• Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.

  Biopharmaceutics & drug disposition 20100301

• [Cross reactivity between ACE inhibitors and angiotensin receptor blockers].

  Lakartidningen 20100201

• Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes.

  Life sciences 20100102

• Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.

  Clinical drug investigation 20100101

• Voltammetric determination of candesartan cilexetil in its Cu(II) complex and application to pharmaceutical formulations.

  Journal of AOAC International 20100101

• The different isoforms of the receptor for advanced glycation end products are modulated by pharmacological agents.

  Clinical hemorheology and microcirculation 20100101

• Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

• Angiotensin II receptor blocker candesartan cilexetil, but not hydralazine hydrochloride, protects against mouse cardiac enlargement resulting from undernutrition in utero.

  Reproductive sciences (Thousand Oaks, Calif.) 20091001

• [Pharmacological and clinical properties of ECARD combination tablets LD & HD, fixed-dose combination of candesartan cilexetil and hydrochlorothiazide].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20091001

• Candesartan: widening indications for this angiotensin II receptor blocker?

  Expert opinion on pharmacotherapy 20090801

• Effects of candesartan cilexetil 'add-on' treatment in congestive heart failure outpatients in daily practice.

  Clinical research in cardiology : official journal of the German Cardiac Society 20090601

• Endothelial damage due to impaired nitric oxide bioavailability triggers cerebral aneurysm formation in female rats.

  Journal of hypertension 20090601

• Ask the doctor. After being diagnosed with high blood pressure several years ago, I started taking diltiazem and Atacand. The results were good, giving me an average blood pressure of 110/65. I recently developed gastroenteritis and aspiration pneumonia. While I was in the hospital, my blood pressure got so low I was told to stop taking these medications. I have been off them since, and my blood pressure has remained normal, averaging 105/65. How can this be? Will high blood pressure return?

  Harvard heart letter : from Harvard Medical School 20090601

• [Pharmacological characteristics of ARB and potential strategy to develop novel ARB].

  Nihon rinsho. Japanese journal of clinical medicine 20090401

• Glomerular surface area is normalized in mice born with a nephron deficit: no role for AT1 receptors.

  American journal of physiology. Renal physiology 20090301

• Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20090201

• Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study.

  Diabetes research and clinical practice 20090201

• Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis.

  Journal of pharmacological sciences 20090201

• Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.

  Pharmaceutical development and technology 20090101

• Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil.

  Clinical drug investigation 20090101

• Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.

  Clinical drug investigation 20090101

• Candesartan cilexetil in the treatment of chronic heart failure.

  Vascular health and risk management 20090101

• Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.

  Vascular health and risk management 20090101

• Angiotensin II receptor blockage prevents diabetes-induced oxidative damage in rat heart.

  Folia biologica 20090101

• Pharmacokinetics and antihypertensive effects of candesartan cilexetil in patients undergoing haemodialysis: an open-label, single-centre study.

  Clinical drug investigation 20090101

• Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.

  Vascular health and risk management 20090101

• A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.

  Cardiovascular drugs and therapy 20081201

• Comparison of the effects of candesartan cilexetil and enalapril maleate on right ventricular myocardial remodeling in dogs with experimentally induced pulmonary stenosis.

  American journal of veterinary research 20081201

• Candesartan cilexetil effectively reduces blood pressure in hypertensive children.

  The Annals of pharmacotherapy 20081001

• Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.

  Journal of clinical hypertension (Greenwich, Conn.) 20081001

• Dual renin-angiotensin blockage and total embryo cryopreservation is not a risk-free strategy in patients at high risk for ovarian hyperstimulation syndrome.

  Fertility and sterility 20080901

• Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease.

  Clinical and experimental nephrology 20080801

• Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.

  Journal of hypertension 20080701

• Behçet's disease complicated by IgA nephropathy with nephrotic syndrome.

  Clinical and experimental nephrology 20080601

• Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts.

  Digestive diseases and sciences 20080501

• Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected.

  The journal of obstetrics and gynaecology research 20080401

• Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.

  Clinical and experimental nephrology 20080201

• [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ].

  MMW Fortschritte der Medizin 20080117

• Angiotensin II AT(1) receptor blockade selectively enhances brain AT(2) receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive rats.

  Stress (Amsterdam, Netherlands) 20080101

• Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.

  Journal of gastroenterology and hepatology 20071101

• Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes.

  Experimental eye research 20070901

• Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20070901

• Hydrolysis and transesterification reactions of candesartan cilexetil observed during the solid phase extraction procedure.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070815

• Expression of angiotensin II receptor type 1 is reduced in advanced rat liver fibrosis.

  Digestive diseases and sciences 20070801

• [Efficacy of candesartan cilexetil in hypertensive patients with or without diabetes].

  Archives des maladies du coeur et des vaisseaux 20070801

• Additive renoprotective effect of candesartan and tetrahydrobiopterin in rats after 5/6 nephrectomy.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070701

• Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.

  Current medical research and opinion 20070701

• AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers.

  Journal of hepatology 20070601

• [ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].

  Nihon rinsho. Japanese journal of clinical medicine 20070528

• Palatability of angiotensin II antagonists among nephropathic children.

  British journal of clinical pharmacology 20070501

• [Treatment of high-normal blood pressure with angiotensin receptor blockers. TROPHY Study (Trial of Preventing Hypertension)].

  Der Internist 20070401

• [Effects of angiotensin II type 1 receptor blocker on islet of diabetic db/db mice].

  Zhonghua nei ke za zhi 20070401

• pH-responsive polymeric micelles of poly(ethylene glycol)-b-poly(alkyl(meth)acrylate-co-methacrylic acid): influence of the copolymer composition on self-assembling properties and release of candesartan cilexetil.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20070301

• Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis.

  Laboratory investigation; a journal of technical methods and pathology 20070201

• Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials.

  Vascular health and risk management 20070201

• [Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension].

  Deutsche medizinische Wochenschrift (1946) 20070119

• Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart.

  Journal of cardiovascular pharmacology 20070101

• Developmental activity of the renin-angiotensin system during the 'critical period' modulates later L-NAME-induced hypertension and renal injury.

  Hypertension research : official journal of the Japanese Society of Hypertension 20070101

• A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.

  Clinical drug investigation 20070101

• Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma.

  European journal of pharmacology 20061215

• Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.

  Journal of clinical pharmacy and therapeutics 20061201

• Effects of benidipine, a long-lasting dihydropyridine-Ca2+ channel blocker, on cerebral blood flow autoregulation in spontaneously hypertensive rats.

  Biological & pharmaceutical bulletin 20061101

• Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4.

  The Journal of pharmacy and pharmacology 20061101

• Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.

  Pediatric nephrology (Berlin, Germany) 20061001

• A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.

  American heart journal 20061001

• Inhibitory effect of candesartan cilexetil on left ventricular remodeling after myocardial infarction.

  International heart journal 20060901

• A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study.

  Vascular health and risk management 20060901

• Different effects of angiotensin receptor blockade on end-organ damage in salt-dependent and salt-independent hypertension.

  Circulation 20060829

• [CASE-J].

  Nihon rinsho. Japanese journal of clinical medicine 20060801

• Treating prehypertension.

  The New England journal of medicine 20060727

• Treating prehypertension.

  The New England journal of medicine 20060727

• Treating prehypertension.

  The New England journal of medicine 20060727

• Treating prehypertension.

  The New England journal of medicine 20060727

• Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20060701

• Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice.

  Biochemical and biophysical research communications 20060616

• Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus.

  Journal of atherosclerosis and thrombosis 20060601

• Pharmacotherapy for prehypertension--mission accomplished?

  The New England journal of medicine 20060420

• Feasibility of treating prehypertension with an angiotensin-receptor blocker.

  The New England journal of medicine 20060420

• Effect of nos inhibition on retinal arterial and capillary circulation in early arterial hypertension.

  Retina (Philadelphia, Pa.) 20060401

• A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.

  International journal of clinical practice 20060401

• Effect of Angiotensin II Type 1 receptor blocker on cardiac angiotensin-converting enzyme and chymase-like activities, and cardiac fibrosis in cardiomyopathic hamsters.

  The Journal of veterinary medical science 20060301

• Candesartan cilexetil on regular hemodialysis: inability to reduce excessive thirst, but good tolerance and efficacy in hypertensive patients.

  Renal failure 20060101

• Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.

  PharmacoEconomics 20060101

• Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.

  Clinical drug investigation 20060101

• Perspectives on prehypertension.

  Journal of the cardiometabolic syndrome 20060101

• [Candesartan Cilexetil (Atacand) induced prolonged severe cholestasis improved by extracorporeal albumin dialysis].

  Gastroenterologie clinique et biologique 20051201

• Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.

  The American journal of the medical sciences 20051001

• Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.

  British journal of clinical pharmacology 20050801

• Angiotensin blockade inhibits osteopontin expression in non-infarcted myocardium after myocardial infarction.

  Journal of pharmacological sciences 20050701

• Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.

  Current medical research and opinion 20050601

• Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

  Biopharmaceutics & drug disposition 20050501

• Mechanisms of combined treatment with celiprolol and candesartan for ventricular remodeling in experimental heart failure.

  Circulation journal : official journal of the Japanese Circulation Society 20050501

• Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.

  European journal of pharmacology 20050411

• Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.

  Hypertension (Dallas, Tex. : 1979) 20050401

• Treatment with AT(1) receptor blocker restores diabetes-induced alterations in intracellular Ca(2+) transients and contractile function of rat myocardium.

  Archives of biochemistry and biophysics 20050301

• Physicians' attitudes towards and reasons for participation in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.

  Journal of epidemiology 20050301

• Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus.

  Hypertension (Dallas, Tex. : 1979) 20050201

• Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth.

  Carcinogenesis 20050201

• ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure.

  Journal of hypertension 20050201

• Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.

  Journal of hypertension 20050201

• Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study.

  Journal of hypertension 20050201

• Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.

  Chinese medical journal 20050120

• Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050101

• Examination of 209 drugs for inhibition of cytochrome P450 2C8.

  Journal of clinical pharmacology 20050101

• The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance.

  American heart journal 20050101

• Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients.

  International journal of clinical practice 20050101

• Candesartan cilexetil: a review of its use in the management of chronic heart failure.

  Drugs 20050101

• Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy.

  Molecular and cellular biochemistry 20050101

• [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].

  Arzneimittel-Forschung 20050101

• Two- and three-drug therapy with candesartan cilexetil (Atacand) successful in patients with severe hypertension.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20050101

• Angiotensin receptor gene expression in candesartan mediated neuroprotection.

  Neuroreport 20041203

• Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.

  Journal of human hypertension 20041201

• Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.

  Journal of human hypertension 20041201

• Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure.

  American journal of physiology. Heart and circulatory physiology 20041201

• Candesartan cilexetil in cardiovascular disease.

  Expert review of cardiovascular therapy 20041101

• Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade.

  Journal of molecular and cellular cardiology 20041101

• [Long-term effects of TCV116 on cardiac function changes after myocardial infarction].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20041101

• Anodic adsorptive stripping voltammetry of the antihypertensive drug candesartan cilexetil at a glassy carbon electrode.

  Die Pharmazie 20041101

• Effects of AT1 receptor antagonist and spironolactone on cardiac expression of ET-1 mRNA in SHR-SP/Izm.

  Journal of cardiovascular pharmacology 20041101

• Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model.

  Circulation 20041005

• Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.

  Diabetes research and clinical practice 20041001

• Are angiotensin receptor blockers neuroprotective?

  Current hypertension reports 20040801

• Candesartan for the treatment of hypertension and heart failure.

  Expert opinion on pharmacotherapy 20040701

• Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20040701

• Impaired endothelial function of the retinal vasculature in hypertensive patients.

  Stroke 20040601

• Candesartan prevents myocardial fibrosis during progression of congestive heart failure.

  Journal of cardiovascular pharmacology 20040601

• Erythema multiforme associated with candesartan cilexetil.

  Southern medical journal 20040601

• Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension.

  Current medical research and opinion 20040501

• Effect of long-term angiotensin II type I receptor antagonism on peripheral and coronary vasomotion.

  Cardiovascular drugs and therapy 20040501

• Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans.

  Hypertension (Dallas, Tex. : 1979) 20040401

• Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction.

  Circulation journal : official journal of the Japanese Circulation Society 20040401

• Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation.

  Journal of hypertension 20040401

• Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats.

  Kidney international 20040301

• Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.

  Journal of hypertension 20040301

• Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats.

  Diabetologia 20040101

• Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension.

  Diabetes, obesity & metabolism 20040101

• Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist.

  Thorax 20040101

• [Effect of angiotensin II receptor antagonist on heart failure].

  Nihon rinsho. Japanese journal of clinical medicine 20040101

• The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20040101

• CHARM shows improvement in NYHA functional class with candesartan.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20040101

• Importance of the angiotensin type 1 receptor in angiotensin II-induced bronchoconstriction and bronchial hyperresponsiveness in the guinea pig.

  Experimental lung research 20040101

• CHARM study in CHF patients with impaired LV function reinforces benefits of candesartan cilexetil (Atacand).

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20040101

• Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.

  Drugs under experimental and clinical research 20040101

• Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice.

  Journal of the American College of Cardiology 20031203

• Re: Evaluation of acute candesartan cilexetil therapy in stroke survivors.

  Stroke 20031201

• ACCESS study: blood pressure effect?

  Stroke 20031201

• The effects of replacing dihydropyridine calcium-channel blockers with angiotensin II receptor blocker on the quality of life of hypertensive patients.

  Blood pressure. Supplement 20031201

• Application of first derivative UV-spectrophotometry and ratio derivative spectrophotometry for the simultaneous determination of candesartan cilexetil and hydrochlorothiazide.

  Die Pharmazie 20031101

• Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.

  Transplantation 20031027

• Effects of AT1 receptor block begun late in life on normal cardiac aging in rats.

  Journal of cardiovascular pharmacology 20031001

• Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure.

  European journal of heart failure 20031001

• Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM.

  European journal of heart failure 20031001

• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

  Lancet (London, England) 20030906

• Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca(2+) regulatory proteins and extracellular matrix.

  Journal of hypertension 20030901

• Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20030901

• Absence of interactive effects of trans-1,2-cyclohexanediol, a major metabolite of the side-chain of candesartan cilexetil, on digoxin-induced arrhythmias in dogs.

  Journal of pharmacological sciences 20030801

• The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.

  Stroke 20030701

• Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth.

  The Journal of clinical investigation 20030701

• [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].

  Nihon Jinzo Gakkai shi 20030701

• Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.

  Journal of medicinal chemistry 20030605

• Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series.

  Human reproduction (Oxford, England) 20030601

• Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20030601

• Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.

  Hypertension research : official journal of the Japanese Society of Hypertension 20030601

• Candesartan cilexetil-induced severe hepatotoxicity.

  Journal of clinical gastroenterology 20030301

• Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.

  American heart journal 20030301

• The regulation of HGF and TGF-beta by an angiotensin II type 1 receptor antagonist in hepatic ischemia-reperfusion injury.

  Transplantation proceedings 20030201

• Role of protein kinase C-angiotensin II pathway for extracellular matrix production in cultured human mesangial cells exposed to high glucose levels.

  Diabetes research and clinical practice 20030101

• Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy.

  Hypertension research : official journal of the Japanese Society of Hypertension 20030101

• Outcomes data for Atacand: results of the SCOPE study.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20030101

• Candesartan cilexetil induced pustular psoriasis.

  European journal of dermatology : EJD 20030101

• CHARM shows benefits of Atacand for symptomatic heart failure.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20030101

• Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy.

  Kidney international. Supplement 20021201

• Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease.

  Circulation journal : official journal of the Japanese Circulation Society 20021101

• Cognitive associations of subcortical white matter lesions in older people.

  Annals of the New York Academy of Sciences 20021101

• Cardiotoxic interaction of metabolites from a prodrug segment cilexetil (cyclohexyloxy-carbonyloxy-ethyl) with digoxin in the canine failing heart.

  Pharmacological research 20021001

• AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade.

  Hypertension (Dallas, Tex. : 1979) 20021001

• [Tendency and prospect of the development of new ARBs].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• [Ameliorative effects on retinal disorder in diabetic SHRSP (stroke-prone spontaneously hypertensive rat)].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• [A megatrial of ARB in Japan--CASE-J].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20020901

• Systemic and regional hemodynamic and cardiac remodeling effects of candesartan in dilated cardiomyopathic hamsters with advanced congestive heart failure.

  Journal of cardiovascular pharmacology 20020801

• Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats.

  Nephron 20020801

• Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart.

  Cardiovascular research 20020701

• Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.

  Hypertension (Dallas, Tex. : 1979) 20020701

• Can hypertension be prevented? The Danish Hypertension Prevention Project and the Trial of Prevention of Hypertension studies.

  Current opinion in cardiology 20020701

• Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis.

  Biochemical and biophysical research communications 20020607

• Comparison of the effects of antihypertensive treatment with angiotensin II blockade and beta-blockade on carotid wall structure and haemodynamics: protocol and baseline demographics.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20020601

• Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats.

  Journal of hypertension 20020501

• Angiotensin II receptor antagonist improves age-related endothelial dysfunction.

  Journal of hypertension 20020301

• Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.

  Japanese journal of pharmacology 20020301

• TCV-116, an angiotensin II type 1 receptor antagonist, reduces hepatic ischemia-reperfusion injury in rats.

  Transplantation 20020227

• Interaction of digoxin with antihypertensive drugs via MDR1.

  Life sciences 20020215

• Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats.

  Hypertension (Dallas, Tex. : 1979) 20020201

• Suppression of endotoxin-induced renal tumor necrosis factor-alpha and interleukin-6 mRNA by renin-angiotensin system inhibitors.

  Japanese journal of pharmacology 20020201

• Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.

  Diabetes care 20020101

• Clinical pharmacokinetics of candesartan.

  Clinical pharmacokinetics 20020101

• Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.

  Drugs 20020101

• Candesartan cilexetil: an update of its use in essential hypertension.

  Drugs 20020101

• Switching from ACE inhibitors, beta-blockers, calcium antagonists or diuretics to candesartan improves efficacy and tolerability.

  Blood pressure 20020101

• Acute precipitants of congestive heart failure exacerbations.

  Archives of internal medicine 20011022

• Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.

  Kidney international 20011001

• TCV-116 stimulates eNOS and caveolin-1 expression and improves coronary microvascular remodeling in normotensive and angiotensin II-induced hypertensive rats.

  Atherosclerosis 20011001

• [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].

  Nihon rinsho. Japanese journal of clinical medicine 20011001

• Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.

  Journal of hypertension 20010801

• Functional role of endogenous endothelin-1 in congestive heart failure treated with angiotensin II receptor antagonist.

  The Japanese journal of physiology 20010801

• A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II.

  Journal of human hypertension 20010701

• The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.

  Diabetologia 20010701

• Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats.

  Atherosclerosis 20010601

• [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].

  Deutsche medizinische Wochenschrift (1946) 20010511

• A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20010501

• Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.

  Journal of the American Society of Nephrology : JASN 20010401

• Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats.

  American journal of hypertension 20010401

• Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).

  Japanese journal of pharmacology 20010401

• Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.

  The American journal of cardiology 20010315

• Effects of AT1 receptor antagonist on proteoglycan gene expression in hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20010301

• Role of angiotensin II type 1 receptor in the leucocytes and endothelial cells of brain microvessels in the pathogenesis of hypertensive cerebral injury.

  Journal of hypertension 20010301

• Discordant responses to two classes of drugs acting on the renin-angiotensin system.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20010301

• Angiotensin II type 1 receptor blockers.

  Circulation 20010213

• Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group.

  American journal of hypertension 20010201

• Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat.

  Transplant immunology 20010201

• Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN69 dialysis membranes.

  Kidney & blood pressure research 20010101

• Effects of TCV-116 on endothelin-1 and PDGF A-chain expression in angiotensin II-induced hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20010101

• Effect of prolonged nitric oxide synthesis inhibition on plasma fibrinogen concentration in rats.

  Japanese journal of pharmacology 20010101

• Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide.

  Drugs & aging 20010101

• The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.

  Blood pressure 20010101

• Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis.

  BMC nephrology 20010101

• Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study.

  Journal of clinical hypertension (Greenwich, Conn.) 20010101

• Differential effect of chronic inhibition of calcium channel and angiotensin II type 1-receptor on aldosterone synthesis in spontaneously hypertensive rats.

  The Journal of steroid biochemistry and molecular biology 20001001

• KRH-594, a new angiotensin AT1 receptor antagonist, ameliorates nephropathy and hyperlipidaemia in diabetic spontaneously hypertensive rats.

  Clinical and experimental pharmacology & physiology 20000401

• Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy.

  Journal of cardiovascular pharmacology 19991101

• Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo.

  Circulation 19991012

• Role of angiotensin II, endothelin-1, and nitric oxide in HgCl2-induced acute renal failure.

  Toxicology and applied pharmacology 19981001

• Candesartan prevents the progression of mesangioproliferative nephritis in rats.

  Kidney international. Supplement 19971201

• Role of angiotensin II in reflex tachycardia during hypotension caused by a calcium channel blocker.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 19960701

• Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 19960601

• Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.

  Journal of medicinal chemistry 19960202

• Regulation of neuronal nitric oxide synthase in rat adrenal medulla.

  Hypertension (Dallas, Tex. : 1979) 19950301